Found: 30
Select item for more details and to access through your institution.
Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.
- Published in:
- International Journal of Hematology, 2013, v. 98, n. 1, p. 66, doi. 10.1007/s12185-013-1367-z
- By:
- Publication type:
- Article
Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.
- Published in:
- International Journal of Hematology, 2013, v. 97, n. 6, p. 743, doi. 10.1007/s12185-013-1321-0
- By:
- Publication type:
- Article
Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.
- Published in:
- 2011
- By:
- Publication type:
- Case Study
Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Correlation between high serum alkaline phosphatase levels and denosumab‐related hypocalcemia in patients with multiple myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 2, p. 355, doi. 10.1111/bjh.15837
- By:
- Publication type:
- Article
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon‐α and ATRA.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 969, doi. 10.1111/bjh.15673
- By:
- Publication type:
- Article
Pim‐2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 4, p. 581, doi. 10.1111/bjh.14388
- By:
- Publication type:
- Article
Unique anti‐myeloma activity by thiazolidine‐2,4‐dione compounds with Pim inhibiting activity.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 2, p. 246, doi. 10.1111/bjh.15033
- By:
- Publication type:
- Article
Frequent bleeding symptoms associated with autoimmune acquired factor XIII/13 deficiency due to anti‐factor XIII A and B subunit antibodies.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 11, p. 1497, doi. 10.1002/ajh.26685
- By:
- Publication type:
- Article
Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors.
- Published in:
- PLoS ONE, 2013, v. 8, n. 12, p. 1, doi. 10.1371/journal.pone.0083905
- By:
- Publication type:
- Article
Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL.
- Published in:
- PLoS ONE, 2012, v. 7, n. 2, p. 1, doi. 10.1371/journal.pone.0031594
- By:
- Publication type:
- Article
Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells.
- Published in:
- PLoS ONE, 2011, v. 6, n. 11, p. 1, doi. 10.1371/journal.pone.0027222
- By:
- Publication type:
- Article
TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth.
- Published in:
- PLoS ONE, 2010, v. 5, n. 3, p. 1, doi. 10.1371/journal.pone.0009870
- By:
- Publication type:
- Article
The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.
- Published in:
- Cancers, 2020, v. 12, n. 4, p. 929, doi. 10.3390/cancers12040929
- By:
- Publication type:
- Article
Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma.
- Published in:
- Cancers, 2020, v. 12, n. 1, p. 12, doi. 10.3390/cancers12010012
- By:
- Publication type:
- Article
Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement.
- Published in:
- Journal of Medical Investigation, 2021, v. 68, n. 1/2, p. 196, doi. 10.2152/jmi.68.196
- By:
- Publication type:
- Article
Comparison of Autologous Hematopoietic Cell Transplantation and Chemotherapy as Postremission Treatment in Non-M3 Acute Myeloid Leukemia in First Complete Remission.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 6, p. 444, doi. 10.1016/j.clml.2012.07.004
- By:
- Publication type:
- Article
Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation.
- Published in:
- Journal of Cancer Survivorship, 2023, v. 17, n. 3, p. 781, doi. 10.1007/s11764-022-01250-8
- By:
- Publication type:
- Article
Polyclonal immunoglobulin recovery after autologous stem cell transplantation is an independent prognosis factor for survival in patients with multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e215, doi. 10.1016/j.clml.2019.09.358
- By:
- Publication type:
- Article
Synergistic targeting of Sp1 in myeloma cells with hyperthermia plus proteasome inhibitors.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e132, doi. 10.1016/j.clml.2019.09.219
- By:
- Publication type:
- Article
Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e105, doi. 10.1016/j.clml.2019.09.173
- By:
- Publication type:
- Article
Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.
- Published in:
- International Journal of Hematology, 2024, v. 119, n. 3, p. 303, doi. 10.1007/s12185-023-03705-9
- By:
- Publication type:
- Article
Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
- Published in:
- International Journal of Hematology, 2023, v. 117, n. 5, p. 718, doi. 10.1007/s12185-023-03541-x
- By:
- Publication type:
- Article
KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.
- Published in:
- British Journal of Haematology, 2011, v. 155, n. 3, p. 328, doi. 10.1111/j.1365-2141.2011.08844.x
- By:
- Publication type:
- Article
Cryptosporidiosis in a transplant recipient with severe intractable diarrhea: Detection of <italic>Cryptosporidium</italic> oocysts by intestinal biopsies.
- Published in:
- Transplant Infectious Disease, 2018, v. 20, n. 2, p. 1, doi. 10.1111/tid.12826
- By:
- Publication type:
- Article
Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.
- Published in:
- Journal of Bioenergetics & Biomembranes, 2012, v. 44, n. 1, p. 31, doi. 10.1007/s10863-012-9412-9
- By:
- Publication type:
- Article
Constitutional pericentric inversion of chromosome 16, inv(16)(p13.1q22), mimicking acute myeloid leukemia.
- Published in:
- 2022
- By:
- Publication type:
- Case Study